研究单位：[1]Merck Sharp & Dohme LLC[2]Zhongshan Hospital Fudan University ( Site 0049) Shanghai, Shanghai, China, 200032[3]Shanghai Tongji Hospital ( Site 0031) Shanghai, Shanghai, China, 200065[4]Zhongda Hospital Southeast University ( Site 0045) Nanjing, Jiangsu, China, 210009[5]The Second Affiliated Hospital of Nanjing Medical University ( Site 0020) Nanjing, Jiangsu, China, 210011[6]First Affiliated Hospital of Soochow University ( Site 0048) Suzhou, Jiangsu, China, 215006[7]The Affiliated Hospital of Xuzhou Medical University ( Site 0017) Xuzhou, Jiangsu, China, 221000[8]Subei People's Hospital ( Site 0040) Yangzhou, Jiangsu, China, 225001[9]Second Affiliated Hospital of Nanchang University ( Site 0038) Nanchang, Jiangxi, China, 330006[10]Guangdong General Hospital ( Site 0006) Guangzhou, Guangdong, China, 510080[11]The First Affiliated Hospital.Sun Yat-sen University ( Site 0007) Guangzhou, Guangdong, China, 510080[12]Sun Yat-sen Memorial Hospital of Sun Yat-sen University ( Site 0008) Guangzhou, Guangdong, China, 510210[13]The First Affiliated Hospital of Baotou Medical College ( Site 0025) Baotou, Anhui, China, 014010[14]Beijing Anzhen Hospital. Capital Medical University ( Site 0001) Beijing, Anhui, China, 100024[15]Aero Space center hospital ( Site 0003) Beijing, Beijing, China, 100049[16]Beijing Friendship Hospital ( Site 0005) Beijing, Beijing, China, 100050[17]Chongqing General Hospital ( Site 0037) Chongqing, Chongqing, China, 400013[18]Lanzhou University Second Hospital ( Site 0041) Lanzhou, Gansu, China, 730030[19]Second Affiliated Hospital of Nanchang University ( Site 0038) Nanchang, Jiangxi, China, 330006
研究目的：
This study will evaluate the EZ/Ator fixed-dose combination (FDC) tablet (MK-0653C) as second line Low-Density Lipoprotein - Cholesterol (LDL-C) treatment in Chinese participants. The primary hypothesis is that MK-0653C 10/10 mg is superior to atorvastatin 20 mg in percent change from baseline in LDL-C to 12 weeks after treatment.
